These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
122 related articles for article (PubMed ID: 23095503)
1. Desmoplastic malignant melanoma: a study of ten cases and status of BRAF mutation. Coupelon S; Franck F; Jarrousse AS; Déchelotte P; Souteyrand P; D'Incan M Dermatology; 2012; 225(2):168-71. PubMed ID: 23095503 [TBL] [Abstract][Full Text] [Related]
2. Lymph node metastases of melanoma: challenges for BRAF mutation detection. Chen G; Dudley J; Tseng LH; Smith K; Gurda GT; Gocke CD; Eshleman JR; Lin MT Hum Pathol; 2015 Jan; 46(1):113-9. PubMed ID: 25456393 [TBL] [Abstract][Full Text] [Related]
3. Assessment of clinical parameters associated with mutational status in metastatic malignant melanoma: a single-centre investigation of 141 patients. Schlaak M; Bajah A; Podewski T; Kreuzberg N; von Bartenwerffer W; Wardelmann E; Merkelbach-Bruse S; Büttner R; Mauch C; Kurschat P Br J Dermatol; 2013 Apr; 168(4):708-16. PubMed ID: 23528057 [TBL] [Abstract][Full Text] [Related]
4. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. Long GV; Menzies AM; Nagrial AM; Haydu LE; Hamilton AL; Mann GJ; Hughes TM; Thompson JF; Scolyer RA; Kefford RF J Clin Oncol; 2011 Apr; 29(10):1239-46. PubMed ID: 21343559 [TBL] [Abstract][Full Text] [Related]
5. Expression of AID in malignant melanoma with BRAF(V600E) mutation. Okura R; Yoshioka H; Yoshioka M; Hiromasa K; Nishio D; Nakamura M Exp Dermatol; 2014 May; 23(5):347-8. PubMed ID: 24684646 [TBL] [Abstract][Full Text] [Related]
7. Desmoplastic malignant melanoma: a clinicopathologic analysis of 113 cases. de Almeida LS; Requena L; Rütten A; Kutzner H; Garbe C; Pestana D; Gomes MM Am J Dermatopathol; 2008 Jun; 30(3):207-15. PubMed ID: 18496419 [TBL] [Abstract][Full Text] [Related]
8. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes. Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867 [TBL] [Abstract][Full Text] [Related]
9. BRAF mutation screening in melanoma: is sentinel lymph node reliable? Nardin C; Puzenat E; Prétet JL; Algros MP; Doussot A; Puyraveau M; Mougin C; Aubin F Melanoma Res; 2015 Aug; 25(4):328-34. PubMed ID: 26020488 [TBL] [Abstract][Full Text] [Related]
10. RAS and RAF mutations in banal melanocytic aggregates contiguous with primary cutaneous melanoma: clues to melanomagenesis. Dadzie OE; Yang S; Emley A; Keady M; Bhawan J; Mahalingam M Br J Dermatol; 2009 Feb; 160(2):368-75. PubMed ID: 18945298 [TBL] [Abstract][Full Text] [Related]
11. Disease progression and patient survival are significantly influenced by BRAF protein expression in primary melanoma. Safaee Ardekani G; Jafarnejad SM; Khosravi S; Martinka M; Ho V; Li G Br J Dermatol; 2013 Aug; 169(2):320-8. PubMed ID: 23550516 [TBL] [Abstract][Full Text] [Related]
12. NRAS and BRAF mutations in melanoma tumours in relation to clinical characteristics: a study based on mutation screening by pyrosequencing. Edlundh-Rose E; Egyházi S; Omholt K; Månsson-Brahme E; Platz A; Hansson J; Lundeberg J Melanoma Res; 2006 Dec; 16(6):471-8. PubMed ID: 17119447 [TBL] [Abstract][Full Text] [Related]
13. Human malignant melanoma: detection of BRAF- and c-kit-activating mutations by high-resolution amplicon melting analysis. Willmore-Payne C; Holden JA; Tripp S; Layfield LJ Hum Pathol; 2005 May; 36(5):486-93. PubMed ID: 15948115 [TBL] [Abstract][Full Text] [Related]
14. Prognostic value of BRAF mutations in localized cutaneous melanoma. Nagore E; Requena C; Traves V; Guillen C; Hayward NK; Whiteman DC; Hacker E J Am Acad Dermatol; 2014 May; 70(5):858-62.e1-2. PubMed ID: 24388723 [TBL] [Abstract][Full Text] [Related]
15. Incidence of BRAF p.Val600Glu and p.Val600Lys mutations in a consecutive series of 183 metastatic melanoma patients from a high incidence region. Amanuel B; Grieu F; Kular J; Millward M; Iacopetta B Pathology; 2012 Jun; 44(4):357-9. PubMed ID: 22614711 [TBL] [Abstract][Full Text] [Related]
16. BRAF/NRAS mutation frequencies among primary tumors and metastases in patients with melanoma. Colombino M; Capone M; Lissia A; Cossu A; Rubino C; De Giorgi V; Massi D; Fonsatti E; Staibano S; Nappi O; Pagani E; Casula M; Manca A; Sini M; Franco R; Botti G; Caracò C; Mozzillo N; Ascierto PA; Palmieri G J Clin Oncol; 2012 Jul; 30(20):2522-9. PubMed ID: 22614978 [TBL] [Abstract][Full Text] [Related]
17. Marked genetic differences between BRAF and NRAS mutated primary melanomas as revealed by array comparative genomic hybridization. Lázár V; Ecsedi S; Vízkeleti L; Rákosy Z; Boross G; Szappanos B; Bégány A; Emri G; Adány R; Balázs M Melanoma Res; 2012 Jun; 22(3):202-14. PubMed ID: 22456166 [TBL] [Abstract][Full Text] [Related]
18. Cutaneous melanoma subtypes show different BRAF and NRAS mutation frequencies. Saldanha G; Potter L; Daforno P; Pringle JH Clin Cancer Res; 2006 Aug; 12(15):4499-505. PubMed ID: 16899595 [TBL] [Abstract][Full Text] [Related]
19. BRAF gene is somatically mutated but does not make a major contribution to malignant melanoma susceptibility: the Italian Melanoma Intergroup Study. Casula M; Colombino M; Satta MP; Cossu A; Ascierto PA; Bianchi-Scarrà G; Castiglia D; Budroni M; Rozzo C; Manca A; Lissia A; Carboni A; Petretto E; Satriano SM; Botti G; Mantelli M; Ghiorzo P; Stratton MR; Tanda F; Palmieri G; J Clin Oncol; 2004 Jan; 22(2):286-92. PubMed ID: 14722037 [TBL] [Abstract][Full Text] [Related]